Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  decitabine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 62 for your search:
Start Over
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes
Phase: Phase IV
Type: Treatment
Status: Active
Age: 10 to 90
Sponsor: Other
Protocol IDs: MST/MDS-307PLAH-ASH, NCT01674985
A Phase ? Study of Decitabine in Myelodysplastic Syndrome
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DREAM-201, NCT02013102
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 16 to 80
Sponsor: Other
Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767
Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: PLA-BT-010, PLA-S-062, NCT02159820
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
"InDACtion" vs "3+7" Induction in AML
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: EORTC-1301, 2014-001486-27, NCT02172872
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GFM-DAC-CMML, NCT02214407
Haplo-SCT vs ASCT With or Without Decitabine in AML CR1
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SZ3702, ChiCTR-TRC-14004196, NCT02059720
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 200807728, NCT00925132
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: T2009-003, NCT01483690
Phase I/II - Dasatinib and Decitabine
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0333, CA180357, NCI-2012-00014, NCT01498445
MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: UMAN-10-01, NCT01628471
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 to 75
Sponsor: Other
Protocol IDs: CN301-XYK-001, NCT01690507
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: 2652.00, NCI-2012-02224, 2652, P30CA015704, NCT01729845
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CN301-XYK-002, NCT01758367
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 64
Sponsor: Other
Protocol IDs: 2012-1064, NCI-2013-00548, NCT01794702
Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: CHN-PLAGH-BT-002, NCT01799083
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 month to 18 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR102071, DACOGENAML2004, 2013-000390-70, NCT01853228
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201304715, NCT01876641
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2013-0099, NCI-2013-01665, NCT01893320
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GCO 13-1816, MPD-RC 109, P01CA108671, NCT02076191
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 48721, ULEU13049, NCT02109744
Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-0344, NCI-2014-02299, NCT02257138
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UZB-BN-2013-002, NCT02316028
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 2 to 21
Sponsor: Other
Protocol IDs: 14.0855, NCT02332889
Start Over